UNICREDIT BANK/CALL/AMGEN/350/0.1/15.01.25 | Real-time BOERSE MUENCHEN 02:00:41 2024-07-17 am EDT | ||
| 2.02 EUR | 0.00% |
|
| Current month | +57.81% | ||
| 1 month | +108.25% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
Latest news about AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 2.02 | 0.00% |
| 24-07-16 | 2.02 | +3.59% |
| 24-07-15 | 1.95 | -3.47% |
| 24-07-12 | 2.02 | +18.82% |
| 24-07-11 | 1.7 | +7.59% |
Real-time BOERSE MUENCHEN
Last update July 17, 2024 at 02:00 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HC3JAQ |
| ISIN | DE000HC3JAQ9 |
| Date issued | 2023-01-26 |
| Strike | 350 $ |
| Maturity | 2025-01-15 (183 Days) |
| Parity | 10 : 1 |
| Emission price | 1.1 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.43 € |
|---|---|
| Lowest since issue | 0.15 € |
| Spread | 0.12 € |
| Spread % | 5.94% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
333.1
USD
Average target price
317.4
USD
Spread / Average Target
-4.72%
- Stock Market
- Warrants
- Warrant
